Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Rhea-AI Summary
Q32 Bio (Nasdaq: QTTB) reported Q2 2026 results and corporate updates, highlighting positive 36-week topline data from Part B of its SIGNAL-AA Phase 2a trial of bempikibart in severe and very severe alopecia areata. Bempikibart achieved a 35.3% mean SALT score reduction in the modified intent-to-treat analysis and SALT-20 responses of 40.0% (mITT) and 30.3% (ITT) at Week 36, with a generally well-tolerated safety profile and no new safety signals. Patient enrollment and dosing in the SIGNAL-AA open-label extension are ongoing, with OLE data expected in the second half of 2027, and a registration-directed program planned for 1H 2027, subject to regulatory discussions.
Q32 Bio completed a $200 million public offering in July 2026. Cash and cash equivalents were $106.3 million on June 30, 2026, and, combined with offering proceeds, are expected to fund operations through topline Phase 3 results. Q2 2026 research and development expenses were $4.3 million (down from $5.2 million a year earlier), general and administrative expenses were $4.9 million (up from $4.0 million), and net loss was $8.9 million, or $0.44 per share, versus $9.5 million, or $0.78 per share, in Q2 2025.
Positive
- SIGNAL-AA Part B efficacy: 35.3% mean SALT reduction; 40.0% mITT and 30.3% ITT SALT-20 responses at Week 36
- Favorable safety profile: bempikibart generally well-tolerated in Part B with no new safety signals
- $200 million gross proceeds from July 2026 public equity and pre-funded warrant offering
- Cash runway expected to extend through topline Phase 3 results for planned registration-directed bempikibart program
- R&D expenses down to $4.3 million in Q2 2026 from $5.2 million in Q2 2025
- Net loss narrowed to $8.9 million ($0.44/share) from $9.5 million ($0.78/share) year over year
- Venture debt reduced to $0 at June 30, 2026, from $9.7 million at December 31, 2025
Negative
- Continuing net losses: $8.9 million in Q2 2026 and $16.6 million for the first half of 2026
- Rising G&A expenses: $4.9 million in Q2 2026 versus $4.0 million in Q2 2025, driven by higher stock-based compensation and other costs
- Shareholder dilution risk from the July 2026 $200 million common stock and pre-funded warrant offering
- Ongoing high operating expenses: $9.1 million in Q2 2026 despite program rationalization
News Explained
The completed financing adds gross cash while increasing the common-equity base; exact holder dilution is not quantified.
Q32 Bio completed a
Pre-funded warrants are sold at nearly the full share price with a nominal exercise price and convert into shares when exercised. The release does not state the number of shares or warrants issued, their exercise terms, or the resulting ownership dilution, so the exact dilution cannot be assessed from this disclosure.
Against first-quarter operating cash use, the offering gross equals
Sources and calculations
- Q32 Bio second-quarter 2026 results and corporate update (2026-08-05)
- Dilution definition (2026-07-17)
- Pre-funded warrant definition (2026-07-17)
- Q32 Bio first-quarter 2026 fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $200,000,000 / ($6,343,000 / 90) = [object Object]
Market Reaction – QTTB
Following this news, QTTB has declined 1.30%, reflecting a mild negative market reaction. Our momentum scanner has triggered 4 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $15.95.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 05 | Earnings report | Positive | +2.0% | Q1 results maintained trial timing and reported financing-supported operational runway. |
| Mar 10 | Earnings report | Positive | +17.4% | Q4 update included trial enrollment, financing, asset-sale proceeds, and extended runway. |
| Nov 13 | Earnings report | Positive | -9.1% | Enrollment completion and preliminary pharmacokinetic data preceded a negative 24-hour reaction. |
| Aug 06 | Earnings report | Positive | -1.5% | Clinical progress and improved expenses accompanied a negative 24-hour reaction. |
| May 08 | Earnings report | Positive | -1.9% | Fast Track designation and clinical milestones preceded a negative 24-hour reaction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
QTTB's earnings announcements aligned with positive 24-hour reactions in 2 of 5 tag-specific events, while three produced divergent negative reactions.
Key Terms
pharmacokinetic medical
pharmacodynamic medical
anti-drug antibody medical
open-label extension medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
-- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at a medical conference in the second half of 2026 --
-- Patient enrollment and dosing in SIGNAL-AA Part B open-label extension (OLE) ongoing --
-- Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in 1H'2027 subject to planned regulatory discussions later this year --
-- Half-life extended fully human anti-IL-7Rα antibody, ADX-914-XL, advancing in pre-clinical development --
-- Completed
-- Cash and cash equivalents of
"Our progress so far this year has been transformative for Q32 Bio and our bempikibart development program. In July, we reported positive topline results from Part B of our SIGNAL-AA program, demonstrating clinically meaningful efficacy, preliminary signs of durability, and a well-tolerated safety profile in patients with severe and very severe alopecia areata. We look forward to sharing additional details from our 36-week results and initial findings from our 52-week results at an upcoming medical meeting," said Jodie Morrison, Chief Executive Officer of Q32 Bio. "The emerging profile of bempikibart represents a compelling opportunity to address the shortcomings of currently available treatments for patients in need of an effective, safe, and more durable alternative. We believe our data has set the bar for a biologic in alopecia areata and demonstrates the potential for bempikibart to become a standard of care, first-line option for patients."
Ms. Morrison added, "With our recently completed public offering and 36-week Part B results, we are well positioned to advance planned regulatory discussions and initiate a registration-directed program evaluating bempikibart in severe and very severe alopecia areata in the first half of 2027. Additionally, we believe the results observed across bempikibart development to date represent a foundation for broader development, and we are currently evaluating opportunities in expanded alopecia areata populations, as well as in additional I&I indications where IL-7 and TSLP signaling play a role. In parallel, we are advancing a half-life extended development candidate with the same mechanism of action as bempikibart."
Second Quarter 2026 and Recent Business Highlights
- Reported positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial. The Part B portion of the SIGNAL-AA Phase 2a clinical trial is an open-label clinical trial evaluating bempikibart, a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling, in 33 patients with severe or very severe AA with a maximum duration of current episode of four years. Patients are treated with bempikibart for 36 weeks, with off-drug follow-up out to 52 weeks before optional enrollment in the open-label extension ("OLE"). In Part B, bempikibart demonstrated clinically meaningful efficacy on the primary endpoint with a mean percent reduction in Severity of Alopecia Tool ("SALT") score from baseline of
35.3% in the prespecified modified intent-to-treat ("mITT") analysis. Additionally,40.0% of patients achieved a SALT-20 (80% of scalp hair coverage) response at Week 36 in the mITT analysis and30.3% of patients achieved a SALT-20 response at Week 36 in the intent-to-treat ("ITT") analysis of all enrolled patients. In Part B, bempikibart was generally well-tolerated, consistent with prior studies, with no new safety signals, and demonstrated a favorable pharmacokinetic, pharmacodynamic and anti-drug antibody profile. Results from SIGNAL-AA Part B, including additional Week 36 data as well as initial findings from the off-drug period through Week 52, will be presented at a medical meeting in the second half of 2026.
- Patient enrollment and dosing in the SIGNAL-AA Part B OLE remain ongoing. Following completion of the Part B 36-week treatment period and 16-week off-drug follow-up period through Week 52, eligible patients can enroll in an OLE. Enrollment and dosing remain ongoing in the OLE. Analysis from the Part B 16-week off-drug follow-up period and OLE will inform the bempikibart long-term chronic maintenance regimen, which could include monthly, bi-monthly or quarterly dosing, which will be evaluated in future studies. Q32 Bio anticipates data from the Part B OLE in the second half of 2027.
- Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in the first half of 2027 and additional development opportunities being evaluated. Q32 Bio plans to advance bempikibart in patients with severe or very severe AA into a registration-directed program in the first half of 2027 subject to planned regulatory discussions in the second half of 2026. Additionally, based on results observed, Q32 Bio is evaluating opportunities for bempikibart in expanded AA populations as well as in additional immunology and inflammation ("I&I") indications.
- Half-life extended fully human anti-IL-7Rα antibody, ADX-914-XL, advancing in pre-clinical development. Today, Q32 Bio announced that ADX-914-XL, a fully human half-life extended anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling, is advancing in pre-clinical development. Developed using half-life extension technology, ADX-914-XL is designed to provide the clinical activity and safety profile observed to date with bempikibart while offering an extended dosing schedule.
- Completed
$200.0 million $200.0 million
Financial Results
- Cash and cash equivalents were
$106.3 million
- Research and development expenses were
$4.3 million $5.2 million
- General and administrative expenses were
$4.9 million $4.0 million
- Net loss was
$8.9 million $0.44 $9.5 million $0.78
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata1, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
For more information, visit www.Q32Bio.com.
1National Alopecia Areata Foundation
Availability of Other Information About Q32 Bio
Investors and others should note that Q32 Bio communicates with its investors and the public using its website www.Q32Bio.com, including, but not limited to, Q32 Bio's disclosures, investor presentations and FAQs, Securities and Exchange Commission (the "SEC") filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that Q32 Bio posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Q32 Bio encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Q32 Bio's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements contained herein which do not describe historical facts are forward-looking statements, including, among others, Q32 Bio's beliefs, observations, expectations and assumptions regarding the topline data from Part B of the SIGNAL-AA Phase 2a clinical trial and the anticipated timing of its data, the safety, tolerability, clinical activity including biomarker data, potential efficacy and potential benefits of bempikibart including plans and expectations for Part B of the SIGNAL-AA Phase 2a clinical trial, Q32 Bio's expectations and assumptions regarding the timing of reporting the findings from the Part B OLE of the SIGNAL-AA Phase 2a clinical trial, the expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of Q32 Bio's product candidates, including bempikibart, and anticipated milestones, timing of anticipated registrational trials, data readouts and timing, the plans and timing of pre-clinical development regarding ADX-914-XL and Q32 Bio's beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, including statements regarding the sufficiency of its cash and cash equivalents to provide financial runway through topline Phase 3 results from its planned registration-directed program evaluating bempikibart in patients with severe or very severe AA; which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.
Forward-looking statements are based on management's current beliefs and assumptions, which are subject to risks and uncertainties and are not guarantees of future performance. Such risks and uncertainties include, among others, the risk that additional data, or the results of ongoing data analyses, may not support Q32 Bio's current beliefs and expectations for bempikibart, including with respect to the durability of clinical responses, the risk that ongoing and future clinical studies might be more costly than expected or might not yield anticipated results, that Q32 Bio may use its capital resources sooner than currently anticipated, our expectations regarding the sufficiency of our cash and cash equivalents to provide financial runway and that we may need additional funding to complete clinical studies, which may not be available on favorable terms or at all and such other risks and uncertainties identified in Q32 Bio's periodic, current and other filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025 and any subsequent filings with the SEC, which are available at the SEC's website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect Q32 Bio's results of operations and its cash flows, which would, in turn, have a significant and adverse impact on Q32 Bio's stock price. Q32 Bio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Q32 Bio disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
Contacts:
Investors: Brendan Burns
Argot Partners
212.600.1902
Q32Bio@argotpartners.com
Media: David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com
Q32 BIO INC. | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
(in thousands, except share and per share amounts) | ||||||||
(Unaudited) | ||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||
2026 | 2025 | 2026 | 2025 | |||||
Operating expenses: | ||||||||
Research and development | $ 4,259 | $ 5,161 | $ 7,477 | $ 12,286 | ||||
General and administrative | 4,859 | 4,010 | 9,363 | 9,114 | ||||
Total operating expenses | 9,118 | 9,171 | 16,840 | 21,400 | ||||
Loss from operations | (9,118) | (9,171) | (16,840) | (21,400) | ||||
Loss on extinguishment of debt | (147) | — | (147) | — | ||||
Other income (expense), net | 319 | (318) | 432 | 880 | ||||
Total other income (expense), net | 172 | (318) | 285 | 880 | ||||
Net loss and comprehensive loss | $ (8,946) | $ (9,489) | $ (16,555) | $ (20,520) | ||||
Net loss per share—basic and diluted | $ (0.44) | $ (0.78) | $ (0.96) | $ (1.68) | ||||
Weighted-average common shares—basic and diluted | 20,342,345 | 12,197,615 | 17,265,864 | 12,197,615 | ||||
Q32 BIO INC. | ||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||
(in thousands) | ||||
June 30, | December 31, | |||
(Unaudited) | ||||
Assets | ||||
Cash and cash equivalents | $ 106,270 | $ 48,297 | ||
Right-of-use asset, operating leases | 4,770 | 5,100 | ||
Restricted cash and restricted cash equivalents | 647 | 647 | ||
Other assets | 4,180 | 7,732 | ||
Total assets | $ 115,867 | $ 61,776 | ||
Liabilities and stockholders' equity | ||||
Accounts payable, accrued expenses and other current liabilities | $ 5,401 | $ 5,111 | ||
Lease liability, net of current portion | 4,561 | 4,943 | ||
Venture debt | — | 9,708 | ||
Stockholders' equity | 105,905 | 42,014 | ||
Total liabilities and stockholders' equity | $ 115,867 | $ 61,776 | ||
View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-reports-second-quarter-2026-financial-results-and-provides-corporate-update-302843061.html
SOURCE Q32 Bio